



Multiple Abstracts Related to KRYSTEXXA(TM) Development and Treatment Failure Gout to be Presented at the 2009 ACR/ARHP Annual Scientific Meeting

EAST BRUNSWICK, N.J., Sept 08, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced today that five abstracts relating to KRYSTEXXA(TM) (pegloticase) development and treatment failure gout will be presented at the 2009 ACR/ARHP Annual Scientific Meeting taking place in Philadelphia from October 16-21, 2009. The posters will be presented during the "Treatment and Outcome" session on October 19, 2009 and include:

- Chronic Use of Pegloticase: Safety and Efficacy Update (Abstract # 1113)
- October 19, 2009 at 9:00 a.m. Eastern Time

- First Application of Computer-Assisted Analysis of Digital Photographs for Assessing Tophus Response: Phase 3 Studies of Pegloticase in Treatment Failure Gout (Abstract # 1111) - October 19, 2009 at 9:00 a.m. Eastern Time

- Improvement in Health-Related Quality of Life (HRQOL) in Patients with Treatment Failure Gout (TFG) Treated with Pegloticase Measured by SF-6D Derived Utility (Abstract # 1101) - October 19, 2009 at 9:00 a.m. Eastern Time

- Routine Serum Uric Acid (SUA) Monitoring Predicts Antibody-Mediated Loss of Response and Infusion Reaction Risk during Pegloticase Therapy (Abstract # 1104) - October 19, 2009 at 9:00 a.m. Eastern Time

- The Costs of Treatment Failure Gout: A Claims-Based Analysis (Abstract # 1112) - October 19, 2009 at 9:00 a.m. Eastern Time

For complete information on all five abstracts, please visit the American College of Rheumatology website at www.rheumatology.org.

ABOUT SAVIENT PHARMACEUTICALS, INC.

Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and marketing pharmaceutical products that target unmet medical needs in both niche and broader specialty markets. Savient has developed one product: KRYSTEXXA(TM) (pegloticase) which is a PEGylated uricase enzyme intended for the treatment of chronic gout in patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA, formerly referred to as Puricase(R), from Duke University and Mountain View Pharmaceuticals, Inc. Savient also manufactures and supplies Oxandrin(R) (oxandrolone tablets, USP) CIII in the U.S. Further information on Savient can be accessed by visiting: <http://www.savient.com>. Puricase is a registered trademark of Mountain View Pharmaceuticals, Inc.

FORWARD-LOOKING LANGUAGE

All statements other than statements of historical facts included in this press release are forward-looking statements that are subject to certain risks, trends and uncertainties that could cause actual results and achievements to differ materially from those expressed in such statements. These risks, trends and uncertainties are in some instances beyond our control. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "will" and other similar expressions identify forward-looking statements, although not all forward-looking statements contain these identifying words. In particular, any statements regarding potential FDA marketing approval for KRYSTEXXA(TM) (pegloticase) and the efficacy and safety of KRYSTEXXA are forward-looking statements. These forward-looking statements involve substantial risks and uncertainties and are based on our assessment and interpretation of the currently available data and information, our Phase 3 clinical data and on current

expectations, assumptions, estimates and projections about our business and the biopharmaceutical and specialty pharmaceutical industries in which we operate. Important factors that may affect our ability to achieve the matters addressed in these forward-looking statements include, but are not limited to, the possibility that the FDA may raise further issues regarding the BLA for KRYSTEXXA or require that we conduct additional clinical trials; our ability to commercialize and market acceptance of KRYSTEXXA; the delay or failure in completing development of KRYSTEXXA and developing other product candidates; our stock price and market conditions; varying interpretations of our clinical and CMC data by the FDA; delay achieving or failure to achieve FDA approval of KRYSTEXXA; inability to manufacture commercial quantities of our products; inability to gain market acceptance sufficient to justify development and commercialization costs if our products are approved for marketing; our continuing to incur substantial net losses for the foreseeable future; difficulties in obtaining financing; potential development of alternative or more effective products by competitors; reliance on third parties to manufacture, market and distribute many of our products; economic, political and other risks associated with foreign operations; risks of maintaining protection for our intellectual property; risks of an adverse determination in ongoing or future intellectual property litigation; and risks associated with stringent government regulation of the biopharmaceutical industry and other important factors set forth more fully in our reports filed with the Securities and Exchange Commission, to which investors are referred for further information. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements, which speak only as of the date of publication of this press release to shareholders. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we may make. We do not have a policy of updating or revising forward-looking statements and, except as required by law, assume no obligation to update any forward-looking statements.

SVNT - G

SOURCE Savient Pharmaceuticals, Inc.

<http://www.savient.com>

Copyright (C) 2009 PR Newswire. All rights reserved